Gonadotropin replacement in male thalassemia major patients with arrested puberty and acquired hypogonadotropic hypogonadism (AAH): preliminary results and potential factors affecting induction of spermatogenesis
- 38 Downloads
Although spontaneous fertility can occur in well-transfused and well-chelated patients, with β-thalassemia major (β-ΤΜ), the majority are sub fertile due to hypogonadotropic hypogonadism (HH), secondary to transfusional haemosiderosis . Ιn several studies, 40 to 80% of β-ΤΜ patients reported to have arrested puberty, pubertal failure, sexual dysfunction, and infertility [1, 2].
In many non-thalassemic patients with HH, human chorionic gonadotropin (hCG) alone or in combination with human menopausal gonadotropin (hMG) induced spermatogenesis [3, 4, 5]. Very little is known about the induction of spermatogenesis in adolescents and young adult β-TM patients [6, 7]. In this study, we report the preliminary results of gonadotropin replacement for induction of spermatogenesis in five young adult β-TM patients with arrested puberty and acquired hypogonadotropic hypogonadism (AHH), complaining sexual dysfunction and fertility problems.
Patients and methods
Five young adult β-TM patients...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study were in accordance with the ethical standards of Quisisana Hospital and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants, complaining sexual dysfunction and fertility problems, included in the study.
- 2.V. De Sanctis, H. Elsedfy, A.T. Soliman, I.Z. Elhakim, A. Pepe, C. Kattamis, N.A. Soliman, R. Elalaily, M. El Kholy, M. Yassin, Acquired hypogonadotropic hypogonadism (AHH) in thalassaemia major patients: an underdiagnosed condition? Mediterr. J. Hematol. Infect. Dis. https://doi.org/10.4084/MJHID.2016.001 (2016).CrossRefGoogle Scholar
- 5.P.M. Bouloux, E. Nieschlag, H.G. Burger, N.E. Skakkebaek, F.C. Wu, D.J. Handelsman, G.H. Baker, R. Ochsenkuehn, A. Syska, R.I. McLachlan, A. Giwercman, A.J. Conway, L. Turner, J.H. van Kuijk, G. Voortman, Induction of spermatogenesis by recombinant follicle-stimulating hormone (puregon) in hypogonadotropic azoospermic men who failed to respond to human chorionic gonadotropin alone. J. Androl. 24(4), 604–611 (2003)CrossRefGoogle Scholar
- 9.A.A. Dwyer, G.P. Sykiotis, F.J. Hayes, P.A. Boepple, H. Lee, K.R. Loughlin, M. Dym, P.M. Sluss, W.F. Crowley Jr, N. Pitteloud, Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 98(11), E1790–E1795 (2013)CrossRefGoogle Scholar
- 10.S. Bhasin, G.R. Cunningham, F.J. Hayes, A.M. Matsumoto, P.J. Snyder, R.S. Swerdloff, V.M. Montori, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95(6), 2536–2559 (2010)CrossRefGoogle Scholar
- 14.D.W. Warne, G. Decosterd, H. Okada, Y. Yano, N. Koide, C.M. Howles, A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle stimulating hormone and human chorionic gonadotropin. Fertil. Steril. 92(2), 594–604 (2009)CrossRefGoogle Scholar
- 19.A. Soliman, V. De Sanctis, H. Elsedfy, M. Yassin, N. Skordis, M. Karimi, P. Sobti, G. Raiola, M. El Kholy, Growth hormone deficiency in adults with thalassemia: an overview and the I-CET recommendations. Georgian Med. News 222, 79–88 (2013)Google Scholar